188 related articles for article (PubMed ID: 38505611)
21. Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides.
Laverman P; Joosten L; Eek A; Roosenburg S; Peitl PK; Maina T; Mäcke H; Aloj L; von Guggenberg E; Sosabowski JK; de Jong M; Reubi JC; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1410-6. PubMed ID: 21461732
[TBL] [Abstract][Full Text] [Related]
22. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
[TBL] [Abstract][Full Text] [Related]
23. A Systematic Investigation into the Influence of Net Charge on the Biological Distribution of Radiometalated Peptides Using [
Raheem SJ; Salih AK; Garcia MD; Sharpe JC; Toosi BM; Price EW
Bioconjug Chem; 2023 Mar; 34(3):549-561. PubMed ID: 36800496
[TBL] [Abstract][Full Text] [Related]
24. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
25. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin.
Laverman P; Roosenburg S; Gotthardt M; Park J; Oyen WJ; de Jong M; Hellmich MR; Rutjes FP; van Delft FL; Boerman OC
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):386-92. PubMed ID: 17934729
[TBL] [Abstract][Full Text] [Related]
26. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
27. Introduction of a fatty acid chain modification to prolong circulatory half-life of a radioligand towards glucose-dependent insulinotropic polypeptide receptor.
Khalil A; Hakhverdyan S; Cheung P; Bossart M; Wagner M; Eriksson O; Velikyan I
Nucl Med Biol; 2024; 128-129():108876. PubMed ID: 38241936
[TBL] [Abstract][Full Text] [Related]
28. Exploiting the Concept of Multivalency with
Summer D; Rangger C; Klingler M; Laverman P; Franssen GM; Lechner BE; Orasch T; Haas H; von Guggenberg E; Decristoforo C
Contrast Media Mol Imaging; 2018; 2018():3171794. PubMed ID: 29849512
[TBL] [Abstract][Full Text] [Related]
29. Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the
von Guggenberg E; Uprimny C; Klinger M; Warwitz B; Sviridenko A; Bayerschmidt S; di Santo G; Virgolini IJ
J Nucl Med; 2023 Jun; 64(6):859-862. PubMed ID: 36657979
[TBL] [Abstract][Full Text] [Related]
30. Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression.
Summer D; Kroess A; Woerndle R; Rangger C; Klingler M; Haas H; Kremser L; Lindner HH; von Guggenberg E; Decristoforo C
PLoS One; 2018; 13(7):e0201224. PubMed ID: 30059514
[TBL] [Abstract][Full Text] [Related]
31. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.
Roosenburg S; Laverman P; Joosten L; Eek A; Oyen WJ; de Jong M; Rutjes FP; van Delft FL; Boerman OC
Bioconjug Chem; 2010 Apr; 21(4):663-70. PubMed ID: 20302291
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging.
Aloj L; Caracò C; Panico M; Zannetti A; Del Vecchio S; Tesauro D; De Luca S; Arra C; Pedone C; Morelli G; Salvatore M
J Nucl Med; 2004 Mar; 45(3):485-94. PubMed ID: 15001692
[TBL] [Abstract][Full Text] [Related]
33. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
34.
Rangger C; Klingler M; Balogh L; Pöstényi Z; Polyak A; Pawlak D; Mikołajczak R; von Guggenberg E
Mol Pharm; 2017 Sep; 14(9):3045-3058. PubMed ID: 28728415
[TBL] [Abstract][Full Text] [Related]
35. Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue.
Pfister J; Summer D; Rangger C; Petrik M; von Guggenberg E; Minazzi P; Giovenzana GB; Aloj L; Decristoforo C
EJNMMI Res; 2015 Dec; 5(1):74. PubMed ID: 26669693
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [
Grzmil M; Qin Y; Schleuniger C; Frank S; Imobersteg S; Blanc A; Spillmann M; Berger P; Schibli R; Behe M
Theranostics; 2020; 10(24):10861-10873. PubMed ID: 33042258
[No Abstract] [Full Text] [Related]
37. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
38. Gallium-67-labeled lactam bridge-cyclized alpha-MSH peptides with enhanced melanoma uptake and reduced renal uptake.
Guo H; Gallazzi F; Miao Y
Bioconjug Chem; 2012 Jun; 23(6):1341-8. PubMed ID: 22621181
[TBL] [Abstract][Full Text] [Related]
39. Preparation,
Barta P; Kamaraj R; Kucharova M; Novy Z; Petrik M; Bendova K; Hajduch M; Pavek P; Trejtnar F
Bioconjug Chem; 2022 Oct; 33(10):1825-1836. PubMed ID: 36197842
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
